Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: Mechanism and location of action

doi:10.1016/j.resp.2014.06.002

Paper

Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: Mechanism and location of action

Published Aug 15, 2014 · E. Mosca, P. Ciechanski, A. Roy

Respiratory Physiology & Neurobiology

Q2 SJR score

14

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Methylxanthine therapy reverses opioid-induced respiratory depression in neonatal rats by acting centrally, predominantly through inhibition of cAMP-dependent phosphodiesterase-4.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: Mechanism and location of action

References

Citations